Brief: GenSight Says Efficacy, Safety Of Bilateral LUMEVOQ Injections

Gensight Biologics SA

14/12/2021 06:38

Dec 14 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS CONFIRMS SUSTAINED EFFICACY AND SAFETY
OF
BILATERAL LUMEVOQ INJECTIONS AT 2-YEAR FOLLOW-UP OF REFLECT
PHASE III TRIAL
    * SUSTAINED EFFICACY TWO YEARS AFTER INJECTION:
STATISTICALLY
SIGNIFICANT VISUAL ACUITY IMPROVEMENT FROM BASELINE AND NADIR IN
LUMEVOQ-TREATED EYES
    * 73% OF BILATERALLY TREATED SUBJECTS EXPERIENCED AT LEAST
+15
ETDRS LETTERS VERSUS. NADIR
    * BETTER EFFICACY FOR BILATERALLY TREATED SUBJECTS, COUPLED
WITH
FAVORABLE SAFETY PROFILE
    * RESULTS OF 4-YEAR FOLLOW-UP OF RESTORE ARE EXPECTED TO BE
AVAILABLE IN JANUARY 2022

Source text for Eikon:  ID:nBwc6Y8h0a 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))